



200.1079CON

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.: 10/033,055 Confirmation No.: 7860
Applicant: Ronald M. Burch, et al.
Filed: 12/27/2001
Art Unit: 1639
Examiner: Bennett M. Celsa
For: **Analgesic Combination of Oxycodone and Celecoxib**

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

October 27, 2004

INFORMATION DISCLOSURE STATEMENT

Sir:

In accordance with Applicant's duty of disclosure under 37 C.F.R. § 1.56 and the provisions of 37 C.F.R. §§ 1.97 and 1.98, Applicants hereby make of record the single document listed on the accompanying Form PTO-1449 for consideration by the Examiner in connection with the examination of the above-identified patent application.

The document reports the assessment of the effects of combined administration of oxycodone with either of celecoxib, etodolac or rofecoxib, as performed by Purdue Pharma L.P., which is associated with the assignee of the present invention.

This Information Disclosure Statement is being filed after a First Office Action but before a Final Office Action or Notice of Allowance. Pursuant to 37 C.F.R. § 1.98(c), a check for \$180.00 is enclosed to cover the required fee. However, if it is determined that any fee is due, the Examiner is authorized to charge said fee to Attorney Deposit Account No. 50-0552.

11/01/2004 BABRAHA1 00000079 10033055


02 FC:1806

180.00 0P

It is respectfully requested that the reference cited on the accompanying Form PTO-1449 be considered and made of record.

Respectfully submitted,

DAVIDSON, DAVIDSON & KAPPEL, LLC

By: 

Robert J Paradiso

Reg. No. 41,240

DAVIDSON, DAVIDSON & KAPPEL, LLC
Patents, Trademarks and Copyrights
485 Seventh Avenue, 14th Floor
New York, New York 10018
(212) 736-1940

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE		ATTY. DOCKET NO.: 200.1079CON		SERIAL NO.: 10/033,055	
LIST OF PRIOR ART CITED BY APPLICANT (Use several sheets if necessary)		APPLICANT(S): Ronald BURCH et al. FILING DATE: December 27, 2001					
U.S. PATENT DOCUMENTS							
*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA						
	AB						
	AC						
FOREIGN PATENT DOCUMENTS							
		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
	AD						Yes No
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)							
AE	Purdue Discovery Research, Department of Neuropharmacology Study Report "Assessment of the Effects of Combined Administration of Oxycodone and Cox II Inhibitors, Celecoxib, Etodolac and Rofecoxib, in the Rat FCA Model of Inflammatory Pain"; July 28, 2003						
AF							
AG							
AH							
AI							
AJ							
AK							
AL							
AM							
AN							
AO							
AP							
AQ							
AR							
AS							
EXAMINER				DATE CONSIDERED			
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.							

FORM PTO-1449 (REV. 7-80)		U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE				ATTY. DOCKET NO.: 200.1079CON		SERIAL NO.: 10/033,055	
OCT 29 2004 LIST OF PRIOR ART CITED BY APPLICANT (Use several lines if necessary)						APPLICANT(S): Ronald BURCH et al.			
						FILING DATE: December 27, 2001		GROUP: 1639	
U.S. PATENT DOCUMENTS									
*EXAMINER INITIAL		DOCUMENT NUMBER			DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA								
	AB								
	AC								
FOREIGN PATENT DOCUMENTS									
		DOCUMENT NUMBER			DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION
									Yes No
	AD								
OTHER PRIOR ART (Including Author, Title, Date, Pertinent Pages, Etc.)									
	AE	The Merck Index, 12 th edition, Merck & Co. Publishers, p.1194 (1996)							
	AF	Goodman and Gillman's The Pharmacological Basis of Therapeutics, 6 th edition, Macmillan Publishing Co., "Chapter 22: Opioid Analgesics and Antagonists," p.494-497, esp. Tables 22-1, p. 496 (1980)							
	AG	Rorarius et al. , "Non-steroidal Anti-inflammatory Drugs for Postoperative Pain Relief," Current Opinion in Anesthesiology , 7:358-362 (1994)							
	AH	Friedel et al., "Nabumetone- A Reappraisal of its Pharmacology and Therapeutics Use in Rheumatic Diseases," Drugs Vol. 45 (1), pp.131-156 (1993)							
	AI	Eversmeyer et al., "Safety Experience With Nabumetone Versus Diclofenac, Naproxen, Ibuprofen, and Piroxicam in Osteoarthritis and Rheumatoid Arthritis, The American Journal of Medicine, Vol. 95 (Suppl. 2A) pp. 10S-18S							
	AJ	Tanaka et al., "Pharmacological Studies of the New Antiinflammatory Agent 3-Formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one," Arzneim-Forsch./Drug res. 42 (II), Nr. 7, pp. 935-944 (1992)							
	AK	Engelhardt et al., "Anti-inflammatory, Analgesic, Antipyretic and Related Properties of Meloxicam, a New Non-steroidal Anti-inflammatory Agent with Favorable Gastrointestinal Tolerance," Inflamm. Res. 44:423-433 (1995)							
	AL	Engelhardt, "Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2," Brit. J. Rheumatology 1996:35 (suppl. 1): 4-12							
	AM	Distel et al., "Safety of Meloxicam: A Global Analysis of Clinical Trials," Brit. J. Rheumatology 1996:35 (suppl. 1):68-77							
	AN	Wojtulewski et al., " a Six Month Double-blind Trial to Compare the Efficacy and Safety of Meloxicam 7.5 mg Daily and Naproxen 750 mg Daily in Patients with Rheumatoid Arthritis," Brit. J. Rheumatology 1996:35 (suppl. 1):22-28							
	AO	Lipani, "Clinical Update of the Relative Safety of Nabumetone in Long-Term Clinical Trials," Inflammopharmacology (1995) Vol.3(4) pp. 351-361							
	AP	Swingle et al., "Preclinical Pharmacological Studies With Nimesulide," Drugs Exptl. Clin. Res. Vol. X (8-9) pp. 587-597							
	AQ	Rabasseda, "Nimesulide: A Selective Cyclooxygenase 2 inhibitor Antiinflammatory Drug," Drugs of Today Vol 32, No.5 (1996), p9. 365-384							
	AR	Siebert et al., "Pharmacological and Biochemical Demonstration of the Role of Cyclooxygenase 2 in Inflammation and Pain," PNAS USA Vol.91 (Dec. 1994) pp. 12013-12-17							
	AS	Richardson et al., "The Clinical Implications of Inhibition of the Inducible Form of Cyclo-oxygenase," Drug Safety Vol. 15(4), pp. 249-260 (Oct. 1996)							
EXAMINER					DATE CONSIDERED				
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.									